Abstract
Background Despite past and ongoing efforts to achieve health equity in the United States, persistent disparities in socioeconomic status along with multilevel racism maintain disparate outcomes and appear to be amplified by COVID-19.
Objective Measure socioeconomic factors and primary language effects on the risk of COVID-19 severity across and within racial/ethnic groups.
Design Retrospective cohort study.
Setting Health records of 12 Midwest hospitals and 60 clinics in the U.S. between March 4, 2020 to August 19, 2020.
Patients PCR+ COVID-19 patients.
Exposures Main exposures included race/ethnicity, area deprivation index (ADI), and primary language.
Main Outcomes and Measures The primary outcome was COVID-19 severity using hospitalization within 45 days of diagnosis. Logistic and competing-risk regression models (censored at 45 days and accounting for the competing risk of death prior to hospitalization) assessed the effects of neighborhood-level deprivation (using the ADI) and primary language. Within race effects of ADI and primary language were measured using logistic regression.
Results 5,577 COVID-19 patients were included, 866 (n=15.5%) were hospitalized within 45 days of diagnosis. Hospitalized patients were older (60.9 vs. 40.4 years, p<0.001) and more likely to be male (n=425 [49.1%] vs. 2,049 [43.5%], p=0.002). Of those requiring hospitalization, 43.9% (n=381), 19.9% (n=172), 18.6% (n=161), and 11.8% (n=102) were White, Black, Asian, and Hispanic, respectively.
Independent of ADI, minority race/ethnicity was associated with COVID-19 severity; Hispanic patients (OR 3.8, 95% CI 2.72–5.30), Asians (OR 2.39, 95% CI 1.74–3.29), and Blacks (OR 1.50, 95% CI 1.15–1.94). ADI was not associated with hospitalization. Non-English speaking (OR 1.91, 95% CI 1.51–2.43) significantly increased odds of hospital admission across and within minority groups.
Conclusions Minority populations have increased odds of severe COVID-19 independent of neighborhood deprivation, a commonly suspected driver of disparate outcomes. Non-English-speaking accounts for differences across and within minority populations. These results support the continued concern that racism contributes to disparities during COVID-19 while also highlighting the underappreciated role primary language plays in COVID-19 severity across and within minority groups.
Question Does socioeconomic factors or primary language account for racial disparities in COVID-19 disease severity?
Findings In this observational study of 5,577 adults, race/ethnicity minorities and non-English as a primary language, independent of neighborhood-level deprivation, are associated with increased risk of severe COVID-19 disease.
Meaning Socioeconomic factors do not account for racial/ethnic disparities related to COVID-19 severity which supports further investigation into the racism and highlights the need to focus on our non-English speaking populations.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Author Contribution Concept and design: All authors Acquisition, analysis, or interpretation of data: Ingraham, Usher, Tignanelli Drafting of the manuscript: All authors Critical revision of the manuscript for important intellectual content: All authors Funding Source(s): 1. NIH NHLBI T32HL07741 (NEI) 2. AHRQ R01HS24532 (GBM) 3. AHRQ R01 HS26732 (MGU) 4. AHRQ K12HS026379 (CJT) 5. NIH NCATS KL2TR002492, UL1TR002494
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Minnesota institutional review board (STUDY00001489) which provided a waiver of consent for this study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
NEI ingra107{at}umn.edu
CTJ ctignane{at}umn.edu
GBM gmelton{at}umn.edu
MLA miallen{at}umn.edu
AC anthchar{at}med.unc.edu
CW cwarlick{at}umn.edu
RAD dudley{at}umn.edu
MGU mgusher{at}umn.edu
LNP Laura.Purcell{at}unchealth.unc.edu
BSK basil.karam{at}gmail.com
Revised abstract to a different format
Data Availability
Data is not publically available at this time as it has not been de-identified and remains on a secure server in accordance with HIPPA policy.
